Serum Level of Interleukin-33 and Soluble ST2 and Their Association with Disease Activity in Patients with Behcet’s Disease

다국어 초록 (Multilingual Abstract)

Interleukin (IL)-33 is an important mediator of innate immunity. Behcet’s disease (BD) is an autoinflammatory disorder characterized by hyperactivity of the innate immune response.
We measured serum levels of IL-33 and its receptor soluble ST2 (sST2) in patients with BD to investigate their association with disease activity. Serum levels of both IL-33 and sST2were higher in patients with BD compared with those in normal controls (IL-33: 594.48 ±175.04 pg/mL in BD and 224.23 ± 56.64 pg/mL in normal controls [P = 0.048], sST2:99.01 ± 15.92 pg/mL in BD and 23.56 ± 3.25 pg/mL in normal controls [P < 0.001]). IL-33 and sST2 expression in skin tissue, as shown by immunohistochemistry, was higher in patients with BD compared with that in the normal controls. Serum sST2 level correlated significantly with the BD currently active form (BDCAF), Iranian BD dynamic activity measure (IBDDAM), erythrocyte sedimentation rate and C-reactive protein. Multiple linear regression showed that serum sST2 was an independent factor associated with IBBDAM (regression coefficient, 0.374; P = 0.004), and BDCAF (regression coefficient, 0.236;P = 0.047). These results demonstrate that IL-33 and sST2 are highly expressed in patients with BD and that serum sST2 is an independent factor associated with IBDDAM and BDCAF, suggesting a potential role for sST2 as a surrogate marker of disease activity in patients with BD.

참고문헌 (Reference)

1 Moussion C, "The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel alarmin?" 3 : e3331-, 2008

2 Han GW, "Serum levels of IL-33 is increased in patients with ankylosing spondylitis" 30 : 1583-1588, 2011

3 Mok MY, "Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus" 49 : 520-527, 2010

4 Oshikawa K, "ST2 protein induced by inflammatory stimuli can modulate acute lung inflammation" 299 : 18-24, 2002

5 Mildner M, "Primary sources and immunological prerequisites for sST2 secretion in humans" 87 : 769-777, 2010

6 Yin H, "Pretreatment with soluble ST2 reduces warm hepatic ischemia/ reperfusion injury" 351 : 940-946, 2006

7 홍연식, "Measurement of Interleukin-33 (IL-33) and IL-33 Receptors (sST2 and ST2L) in Patients with Rheumatoid Arthritis" 대한의학회 26 (26): 1132-1139, 2011

8 Kageyama Y, "Involvement of IL- 33 in the pathogenesis of rheumatoid arthritis: the effect of etanercept on the serum levels of IL-33" 22 : 89-93, 2012

9 Kuroiwa K, "Identification of human ST2 protein in the sera of patients with autoimmune diseases" 284 : 1104-1108, 2001

10 Carriere V, "IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin- associated nuclear factor in vivo" 104 : 282-287, 2007

11 Schmitz J, "IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines" 23 : 479-490, 2005

12 Kunisch E, "IL-33 regulates TNF-σ dependent effects in synovial fibroblasts" 29 : 530-540, 2012

13 Ciccia F, "IL-33 is overexpressed in the inflamed arteries of patients with giant cell arteritis" 72 : 258-264, 2013

14 Oboki K, "IL-33 is a crucial amplifier of innate rather than acquired immunity" 107 : 18581-18586, 2010

15 Verri WA Jr, "IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy" 69 : 1697-1703, 2010

16 Oboki K, "IL-33 and IL-33 receptors in host defense and diseases" 59 : 143-160, 2010

17 Chen T, "Elevated serum interleukin- 33 levels in patients with Henoch-Schonlein purpura" 305 : 173-177, 2013

18 Mu R, "Elevated serum interleukin 33 is associated with autoantibody production in patients with rheumatoid arthritis" 37 : 2006-2013, 2010

19 Sayinalp N, "Cytokines in Behcet's disease" 23 : 321-322, 1996

20 Shahram F, "Comparison of existing disease activity indices in the follow-up of patients with Behcet's disease" 19 : 536-541, 2009

21 Bhakta BB, "Behcet's disease: evaluation of a new instrument to measure clinical activity" 38 : 728-733, 1999

22 Yang Z, "Association of increased serum IL- 33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population" 11 : 75-80, 2011

23 Bergers G, "Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor" 13 : 1176-1188, 1994

24 Leung BP, "A novel therapy of murine collagen-induced arthritis with soluble T1/ST2" 173 : 145-150, 2004